Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

Kazuhiko Kakihana; Yuki Fujioka; Wataru Suda; Yuho Najima; Go Kuwata; Satoshi Sasajima; Iyo Mimura; Hidetoshi Morita; Daisuke Sugiyama; Hiroyoshi Nishikawa; Masahira Hattori; Yutaro Hino; Shuntaro Ikegawa; Keita Yamamoto; Takashi Toya; Noriko Doki; Koichi Koizumi; Kenya Honda; Kazuteru Ohashi

doi:10.1182/blood-2016-05-717652

Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

Kazuhiko Kakihana^*, Yuki Fujioka, Wataru Suda, Yuho Najima, Go Kuwata, Satoshi Sasajima, Iyo Mimura, Hidetoshi Morita, Daisuke Sugiyama, Hiroyoshi Nishikawa, Masahira Hattori, Yutaro Hino, Shuntaro Ikegawa, Keita Yamamoto, Takashi Toya, Noriko Doki, Koichi Koizumi, Kenya Honda, Kazuteru Ohashi

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

241 Citations (Scopus)

Abstract

Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.

Original language	English
Pages (from-to)	2083-2088
Number of pages	6
Journal	Blood
Volume	128
Issue number	16
DOIs	https://doi.org/10.1182/blood-2016-05-717652
Publication status	Published - 2016 Oct 20

ASJC Scopus subject areas

Immunology
Biochemistry
Hematology
Cell Biology

Access to Document

10.1182/blood-2016-05-717652

Cite this

Kakihana, K., Fujioka, Y., Suda, W., Najima, Y., Kuwata, G., Sasajima, S., Mimura, I., Morita, H., Sugiyama, D., Nishikawa, H., Hattori, M., Hino, Y., Ikegawa, S., Yamamoto, K., Toya, T., Doki, N., Koizumi, K., Honda, K., & Ohashi, K. (2016). Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood, 128(16), 2083-2088. https://doi.org/10.1182/blood-2016-05-717652

Kakihana, K, Fujioka, Y, Suda, W, Najima, Y, Kuwata, G, Sasajima, S, Mimura, I, Morita, H, Sugiyama, D, Nishikawa, H, Hattori, M, Hino, Y, Ikegawa, S, Yamamoto, K, Toya, T, Doki, N, Koizumi, K, Honda, K & Ohashi, K 2016, 'Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut', Blood, vol. 128, no. 16, pp. 2083-2088. https://doi.org/10.1182/blood-2016-05-717652

@article{054aa78b5c214992b1da2e33373914cc,

title = "Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut",

abstract = "Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.",

author = "Kazuhiko Kakihana and Yuki Fujioka and Wataru Suda and Yuho Najima and Go Kuwata and Satoshi Sasajima and Iyo Mimura and Hidetoshi Morita and Daisuke Sugiyama and Hiroyoshi Nishikawa and Masahira Hattori and Yutaro Hino and Shuntaro Ikegawa and Keita Yamamoto and Takashi Toya and Noriko Doki and Koichi Koizumi and Kenya Honda and Kazuteru Ohashi",

year = "2016",

month = oct,

day = "20",

doi = "10.1182/blood-2016-05-717652",

language = "English",

volume = "128",

pages = "2083--2088",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "16",

}

TY - JOUR

T1 - Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

AU - Kakihana, Kazuhiko

AU - Fujioka, Yuki

AU - Suda, Wataru

AU - Najima, Yuho

AU - Kuwata, Go

AU - Sasajima, Satoshi

AU - Mimura, Iyo

AU - Morita, Hidetoshi

AU - Sugiyama, Daisuke

AU - Nishikawa, Hiroyoshi

AU - Hattori, Masahira

AU - Hino, Yutaro

AU - Ikegawa, Shuntaro

AU - Yamamoto, Keita

AU - Toya, Takashi

AU - Doki, Noriko

AU - Koizumi, Koichi

AU - Honda, Kenya

AU - Ohashi, Kazuteru

PY - 2016/10/20

Y1 - 2016/10/20

N2 - Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.

AB - Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.

UR - http://www.scopus.com/inward/record.url?scp=84992074418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992074418&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-05-717652

DO - 10.1182/blood-2016-05-717652

M3 - Review article

C2 - 27461930

AN - SCOPUS:84992074418

SN - 0006-4971

VL - 128

SP - 2083

EP - 2088

JO - Blood

JF - Blood

IS - 16

ER -

Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this